Business Context and Reporting Period
Company: AnaptysBio, Inc. (ANAB)
Filing Type: Form 10-Q (Unaudited)
Period: Three months ended March 31, 2026
Business Model: Royalty management and biopharma development. The company recently completed a separation on April 20, 2026, spinning off its clinical-stage biopharma assets (rosnilimab, ANB033, ANB101) into a new entity, First Tracks Biotherapeutics (TRAX). AnaptysBio retained the royalty rights from its collaborations with GSK (Jemperli) and Vanda (imsidolimab).
Key Financial Metrics
| Metric (in thousands) | Q1 2026 | Q1 2025 |
|---|---|---|
| Collaboration Revenue | $25,556 | $27,771 |
| Total Operating Expenses | $60,193 | $55,310 |
| Net Loss | $(52,884) | $(39,329) |
| Diluted Net Loss Per Share | $(1.84) | $(1.28) |
| Cash and Cash Equivalents | $248,469 | $98,637 |
| Short-term Investments | $37,986 | $73,442 |
| Total Liquidity (Cash + Investments) | $286,455 | $172,079 |
| Liability for Sale of Future Royalties | $263,742 | $276,528 |
Material Changes vs. Prior Period
- Revenue Decline: Collaboration revenue decreased by $2.2 million (8%) to $25.6 million, driven by lower royalty accruals from GSK's Jemperli sales compared to the prior year.
- Expense Increase: Total operating expenses rose by $4.9 million to $60.2 million. General and Administrative (G&A) expenses surged $12.1 million, primarily due to $8.3 million in legal fees related to the GSK litigation and separation activities, and a $4.9 million increase in stock-based compensation.
- R&D Optimization: Research and Development expenses decreased by $7.2 million to $34.0 million, reflecting a $10.4 million reduction in Rosnilimab clinical costs and a $3.6 million reduction in ANB032 costs, partially offset by increased spending on ANB033.
- Liquidity Position: Cash and cash equivalents increased by $150 million year-over-year, supported by net cash provided by investing activities ($35.0 million) due to the sale and maturity of investments.
- Non-Cash Interest: Non-cash interest expense related to the sale of future royalties increased to $20.9 million from $18.1 million, driven by higher Jemperli sales accelerating the repayment schedule to Sagard.
Outlook, Risks, and Unusual Items
- Post-Separation Focus: Following the April 2026 spin-off, AnaptysBio will operate as a royalty management company. Management expects G&A expenses to decrease in the future as separation-related costs subside.
- Legal Proceedings: The company is engaged in active litigation with GSK/Tesaro in Delaware Chancery Court regarding alleged material breaches of the Collaboration Agreement. A trial is scheduled for July 14, 2026. The court previously dismissed Tesaro's claim that AnaptysBio breached the agreement.
- Stock Repurchase Program: The 2025 Repurchase Program expired on March 31, 2026, with no shares repurchased. A new 2026 Repurchase Program was authorized in March 2026 for up to $100 million.
- Risk Factors: Revenue is heavily dependent on GSK's commercialization of Jemperli. Risks include competition from Keytruda (and future biosimilars), potential patent challenges, and the outcome of the ongoing litigation with GSK.
Investor Verification Checklist
- Litigation Status: Monitor the July 14, 2026 trial date and any potential settlement or ruling that could impact the GSK collaboration and royalty stream.
- Spin-Off Transition: Verify the operational separation of First Tracks Biotherapeutics and the allocation of remaining liabilities and assets.
- Royalty Monetization Liability: Review the effective interest rate (34.9% for Jemperli) and the impact of Jemperli sales volume on the non-cash interest expense and liability reduction.
- Cash Runway: Confirm that the $286.5 million in liquidity is sufficient to cover the reduced operating costs of the royalty-only business model for the next 12 months.
- Patent Expirations: Assess the timeline for Jemperli patent expirations and the potential impact of biosimilar competition on future royalty revenues.